IMUX | Ticker Profile - Titan Protect

IMUX

Immunic, Inc.

Healthcare · Biotechnology · NCM

$12.77

Data: 2026-05-15

✓ ETHICAL PASS

MOAT

MODERATE

Data Confidence: 57.1%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$166M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.84

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-142.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$47.13

+269% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Immunic, Inc.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

https://imux.com

Country: United States Employees: 92 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.3% PASS

Debt must be below 33% of total assets

Cash Ratio

8.8% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.427

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0077

No positive edge detected — the data suggests staying out

Calmar Ratio

0.025

Drawdown risk outweighs the returns — higher risk profile

Annual Return

1.9%

Historical annualised return based on price data

Max Drawdown

-73.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$15.10

15% below the year high

52W Low

$5.06

152% above the year low

Avg Volume

309,948

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

9.9%

Moderate short interest

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-6.74

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

4.92

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.87

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-43,541,752

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-104,287,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$85.00

Target Median

$47.13

Target Low

$19.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2025-06-13	NASH DUANE D	Officer and Director	20,000	$16,694
2025-06-05	NEERMANN JOERG	Director	100,000	$76,700
2025-06-05	TARDIO JASON	President	12,512	$9,884
2025-06-05	TARDIO JASON	President	12,512	$9,884
2025-06-04	VITT DANIEL	Chief Executive Officer	15,000	$11,550
2025-06-04	VITT DANIEL	Officer and Director	15,000	$11,550
2025-06-03	WHALEY GLENN	Chief Financial Officer	45,000	$32,076
2025-06-03	RUDICK RICHARD ALAN	Director	143,075	$100,024
2025-05-30	WHALEY GLENN	Chief Financial Officer	25,000	$14,000
2024-11-12	RUDICK RICHARD ALAN	Director	87,300	$100,369

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go